80 Participants Needed

Danicopan Add-On Therapy for Paroxysmal Nocturnal Hemoglobinuria

Recruiting at 87 trial locations
AP
Overseen ByAlexion Pharmaceuticals, Inc.
Age: Any Age
Sex: Any
Trial Phase: Phase 3
Sponsor: Alexion
Must be taking: C5 inhibitors
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Pivotal Trial (Near Approval)This treatment is in the last trial phase before FDA approval
Prior Safety DataThis treatment has passed at least one previous human trial
Breakthrough TherapyThis drug has been fast-tracked for approval by the FDA given its high promise

Trial Summary

Do I need to stop my current medications for this trial?

The trial information does not specify if you need to stop taking your current medications. It seems likely that you can continue your existing treatment with C5i, as danicopan is an add-on therapy.

What data supports the effectiveness of the drug Danicopan for treating paroxysmal nocturnal hemoglobinuria?

In a study, patients with paroxysmal nocturnal hemoglobinuria who were already on eculizumab and received Danicopan showed a significant increase in hemoglobin levels and a reduction in the need for blood transfusions. This suggests that Danicopan can help improve blood health and reduce symptoms in these patients.12345

How does the drug Danicopan differ from other treatments for paroxysmal nocturnal hemoglobinuria?

Danicopan is unique because it is an oral drug that specifically inhibits complement factor D, a part of the immune system that contributes to the destruction of red blood cells in paroxysmal nocturnal hemoglobinuria (PNH). This approach helps control both intravascular and extravascular hemolysis, offering a novel mechanism compared to existing treatments.678910

What is the purpose of this trial?

This is a single-arm long-term extension study that will enroll participants with PNH who have completed participation in Alexion-sponsored clinical studies with danicopan as an add on therapy to a C5i.

Eligibility Criteria

This trial is for people with Paroxysmal Nocturnal Hemoglobinuria (PNH) who have finished a previous Alexion study using Danicopan as an extra treatment. They must be able to consent, follow the study rules, and be vaccinated against Neisseria meningitidis. Those with conditions that could affect the study or pose risks can't join, nor can women who are pregnant, breastfeeding, or planning pregnancy.

Inclusion Criteria

Patient capable of giving signed informed consent, including compliance with the requirements and restrictions listed in the informed consent form and in this protocol
You took part in a previous study sponsored by Alexion that involved using danicopan along with a C5 inhibitor treatment.
I have been vaccinated against Neisseria meningitidis as required.

Exclusion Criteria

Patient permanently discontinued from danicopan in the parent study for any reason other than enrollment into this LTE study
Any medical condition (for example, cardiac, pulmonary, renal, oncologic, or psychiatric) that, in the opinion of the Investigator, might interfere with participation in the study, pose any added risk to the participant, or confound the assessment of the participant
I am not pregnant, breastfeeding, nor planning to become pregnant during the study.

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive danicopan as an add-on to a background C5i therapy, continuing from the parent study

Up to 3 years

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

Open-label extension

Participants continue to receive danicopan as an add-on therapy to C5i for long-term safety and efficacy assessment

Up to 3 years

Treatment Details

Interventions

  • Danicopan
Trial Overview The trial is testing the long-term safety and effectiveness of Danicopan when added to another drug called a C5 inhibitor in patients with PNH. It's a single-arm extension study meaning everyone gets the same treatment without comparison to a placebo or other medication.
Participant Groups
1Treatment groups
Experimental Treatment
Group I: DanicopanExperimental Treatment1 Intervention
Participants will receive their last dose of danicopan from the parent study the night prior to Day 1 of this LTE study and will continue daily treatment with danicopan together with their background C5i therapy.

Find a Clinic Near You

Who Is Running the Clinical Trial?

Alexion

Lead Sponsor

Trials
247
Recruited
38,600+
Marc Dunoyer profile image

Marc Dunoyer

Alexion

Chief Executive Officer since 2021

PhD in Molecular Biology, University of Brussels

Christophe Hotermans profile image

Christophe Hotermans

Alexion

Chief Medical Officer since 2021

MD, University of Leuven

Alexion Pharmaceuticals, Inc.

Lead Sponsor

Trials
267
Recruited
141,000+
Dr. Alberto R. Martinez profile image

Dr. Alberto R. Martinez

Alexion Pharmaceuticals, Inc.

Chief Medical Officer since 2010

MD from University of Sao Paulo

Marc Dunoyer profile image

Marc Dunoyer

Alexion Pharmaceuticals, Inc.

Chief Executive Officer since 2021

PhD in Molecular Biology

Alexion Pharmaceuticals

Lead Sponsor

Trials
231
Recruited
36,700+
Marc Dunoyer profile image

Marc Dunoyer

Alexion Pharmaceuticals

Chief Executive Officer since 2021

B.A. in Psychology from the University of New Hampshire

Christophe Hotermans profile image

Christophe Hotermans

Alexion Pharmaceuticals

Chief Medical Officer since 2023

MD

Findings from Research

In a phase 2 study involving 13 patients with paroxysmal nocturnal hemoglobinuria (PNH), iptacopan demonstrated significant efficacy, with 12 out of 12 evaluable patients achieving a reduction in serum lactate dehydrogenase (LDH) levels by at least 60% by week 12, indicating effective control of hemolysis.
Iptacopan was well tolerated with no severe adverse events reported, and most patients experienced clinically meaningful improvements in hemoglobin levels, remaining transfusion-free for up to 12 weeks, showcasing its potential as a safe and effective monotherapy for treatment-naïve PNH patients.
Iptacopan monotherapy in patients with paroxysmal nocturnal hemoglobinuria: a 2-cohort open-label proof-of-concept study.Jang, JH., Wong, L., Ko, BS., et al.[2022]
In a phase 2 trial involving 10 untreated patients with paroxysmal nocturnal hemoglobinuria (PNH), danicopan, an oral complement factor D inhibitor, significantly reduced intravascular hemolysis as indicated by a decrease in lactate dehydrogenase (LDH) levels from 5.7 times the upper limit of normal at baseline to 1.8 times at day 28.
The treatment was generally well-tolerated, with only one serious adverse event reported, which resolved without lasting effects, suggesting that danicopan may be a safe option for managing hemolysis in PNH patients.
Danicopan: an oral complement factor D inhibitor for paroxysmal nocturnal hemoglobinuriaRisitano, AM., Kulasekararaj, AG., Lee, JW., et al.[2021]
In a study of 47 patients with autoimmune hemolytic anemia (AIHA) who had inadequate bone marrow response, treatment with recombinant erythropoietin (rEPO) led to a significant increase in hemoglobin levels, with 91% of patients showing a response by 12 months.
rEPO treatment also reduced the need for blood transfusions from 30% to less than 10% within 15 days, demonstrating its efficacy as an adjunct therapy alongside standard immunosuppressive treatments.
Recombinant erythropoietin in autoimmune hemolytic anemia with inadequate bone marrow response: a prospective analysis.Fattizzo, B., Pedone, GL., Brambilla, C., et al.[2023]

References

Phase 2 study of danicopan in patients with paroxysmal nocturnal hemoglobinuria with an inadequate response to eculizumab. [2021]
Addition of danicopan to ravulizumab or eculizumab in patients with paroxysmal nocturnal haemoglobinuria and clinically significant extravascular haemolysis (ALPHA): a double-blind, randomised, phase 3 trial. [2023]
Iptacopan monotherapy in patients with paroxysmal nocturnal hemoglobinuria: a 2-cohort open-label proof-of-concept study. [2022]
[Ex vivo expansion of CD34(+) CD59(+) cells from bone marrow of paroxysmal nocturnal hemoglobinuria patients]. [2017]
Danazol treatment for paroxysmal nocturnal hemoglobinuria. [2019]
Danicopan: an oral complement factor D inhibitor for paroxysmal nocturnal hemoglobinuria [2021]
Fetal haemoglobin augmentation in E/beta(0) thalassaemia: clinical and haematological outcome. [2013]
Hydroxyurea induction of fetal hemoglobin synthesis in sickle-cell disease. [2018]
Recombinant erythropoietin in autoimmune hemolytic anemia with inadequate bone marrow response: a prospective analysis. [2023]
Effect of riboflavin treatment on human red cell pyruvate kinase deficiency. [2019]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security